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nipolar major depression is one of the most
common mental diseases worldwide.
1,2 Unfortunately,
not all patients respond to the available pharmacologi-
cal treatment algorithms and refractory depression is not
uncommon.
3 Furthermore, the underlying pathophysio-
logical mechanisms of this affective disorder are still
under debate.
4 In spite of these neurobiological uncer-
tainties, we are in need of alternative treatment options.
5
Repetitive transcranial magnetic stimulation (rTMS; a
type of TMS that occurs in a rhythmic and repetitive
form) has been put forward as a new technique to treat
this debilitating illness.
6 Current evidence suggests that
rTMS applied to the dorsolateral prefrontal cortex
(DLPFC) is a promising treatment strategy for depres-
sion, but not all patients show a positive outcome.
7,8
Current clinical outcome studies report rather modest
superiority compared with placebo (sham).
9-11To date, it
remains unclear which TMS parameters, such as stimu-
lation duration and intensity, can produce the most ben-
efits.
6,8,9,12 Moreover, there is no consensus of the exact
brain localization for individual coil placement.
13 To
answer these important questions, it would be important
to gain more insight in the underlying neurobiological
working mechanisms of rTMS. To date, no clear theo-
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For nearly two decades now, transcranial magnetic stim-
ulation (TMS) has been available as a noninvasive clini-
cal tool to treat patients suffering from major depres-
sion. In this period, a bulk of animal and human studies
examined TMS parameters to improve clinical outcome.
However, the neurobiological mechanisms underlying
mood changes remain an important focus of research.
In addition to having an effect on neuroendocrinologi-
cal processes, neurotransmitter systems, and neu-
rotrophic factors, TMS may not only affect the stimu-
lated cortical regions, but also those connected to them.
Therefore, we will review current human data on pos-
sible neurobiological mechanisms of repetitive (r) TMS
implicated in the deregulated neurocircuitry present in
unipolar depression. Furthermore, as the rTMS applica-
tion can be considered as a “top-down” neuronal inter-
vention, we will focus on the neuronal pathways linked
with the stimulated area and we will present an inte-
grative model of action. 
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retical framework has yet emerged as to why rTMS
treatment could result in a “normalization” of mood in
depressed patients.
14,15
rTMS, the dorsolateral prefrontal cortex,
and unipolar depression
The majority of rTMS treatment studies target the
DLPFC.
15,17The (dorsolateral) prefrontal cortex is impli-
cated in regulating affective states, providing cognitive
control over stress and emotion responsiveness.
18A vari-
ety of studies has shown that a series of daily sessions of
high frequency (HF)-rTMS delivered to the left DLPFC
or low frequency (LF)-rTMS applied to the right
DLPFC are effective in reducing symptoms in clinically
depressed populations.
10,11,15 rTMS can either activate or
suppress motor, sensory, or cognitive functions, depend-
ing on the brain location and parameters of its delivery:
LF-rTMS (≤1Hz) is considered to “inhibit” cortical
regional activity, while HF-rTMS (>1Hz) “activates” cor-
tical areas.
19,20The stimulation effects not only affect neu-
ronal activities in the stimulated regions primarily but
also those connected to them secondarily.
21,22 The vast
majority of rTMS studies in major depression target the
left DLPFC with HF stimulation.
10
The rationale to use the DLPFC as the rTMS target area
originates from brain imaging research, where patients
with unipolar depression show prefrontal abnormalities
(predominantly on the left).
23,24 Decreased neuronal
activities in the (dorsolateral) prefrontal regions, as well
as in the rostral anterior cingulate cortex (ACC) areas,
closely connected to the DLPFC, are often reported.
23
These frontal hypoactivities result in apathy, psychomo-
tor slowness, and impaired executive functioning.
Besides dysfunctional “frontocingulate networks,” other
neuronal pathways between the orbital and medial pre-
frontal cortex, the amygdala, and hippocampus are
implicated in the pathophysiology of mood disorders.
24,25
Endocrinological disturbances and hypothalamic-pitu-
itary-adrenal (HPA) system deregulations are commonly
found.
26,27 The most consistently described biological
abnormality in chronic major depression is a failing neg-
ative feedback system resulting in hypercortisolism
28
(Figure 1). 
Brain imaging studies and rTMS
Brain imaging results suggest that antidepressant
response to rTMS might vary as a function of stimula-
tion frequency
29,30 and may depend on pretreatment pre-
frontal brain metabolism.
31,32 For instance, the stimula-
Figure 1. Theoretical framework of deregulated cortico-thalamic-
limbic pathways in unipolar major depression. In major depres-
sion there is a pronounced shift in the homeostasis with dimin-
ished activity in the prefrontal cortex (DLPFC and dorsal ACC
- blue), enhanced activity in the amygdala (red) and activation
of the core stress system. Hyperactivity in limbic areas results
in higher neural activities at the hypothalamic level, evoking
higher corticotrophin-releasing hormone (CRH) secretions,
resulting in elevations of cortisol levels. Hippocampal dys-
function may also result in reduction of the inhibitory regula-
tion of the HPA axis, which could then lead to hypercorti-
solemia.
18 The failing negative feedback system results in
chronic hypercortisolemia. In long-term depressive episodes,
chronically elevated levels of cortisol contribute to hippocam-
pal and cortical atrophy
27 and reducing hippocampal ability to
inhibit amygdala hyperactivity.
76 Abnormal modulation of cor-
tical-hippocampal-amygdala pathways may contribute to
chronically hypersensitive stress responses, mediating features
of anxiety, anhedonia, and affective dyscontrol.
76 Additionally,
the dysfunctional ACC fails to serve its inhibitory role in emo-
tional regulation on the amygdala, resulting in further moti-
vational and affective disruption.
77 DLPFC, dorsolateral pre-
frontal cortex; ACC, anterior cingulate cortex; ACTH,
adenocorticotropic hormone; HPA, hypothalamic-pituitary-
adrenal
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tion of prefrontal regions with lower metabolic activity
with HF-rTMS may significantly improve clinical out-
come.
29 However, opposite results, where higher baseline
metabolic activities in the DLPFC bilaterally were asso-
ciated with better clinical outcome, have been reported
as well.
32-35Additionally, higher baseline activities in the
ACC are not only predictive for treatment outcome in
pharmacological antidepressant trials, electrophysiolog-
ical imaging studies, and sleep deprivation studies,
23,36,37
but high pretreatment ACC activities were also a posi-
tive clinical predictor in HF-rTMS treatment proto-
cols.
32,38
Concerning the neurobiological effects, rTMS seems to
influence metabolic activity of the ACC.
39 Whereas
right-sided LF-rTMS showed metabolic ACC
decreases,
40 left-sided HF-rTMS treatment resulted in
higher ACC metabolic activity,
41,42 especially in those
subdivisions of the ACC which are strongly intercon-
nected with DLPFC areas.
17,32 However, in some reports
successful HF-rTMS treatment did not result in signif-
icant ACC metabolic increases.
43 Furthermore,
Luborzewski et al
44 failed to demonstrate neurochemi-
cal ACC alterations post HF-rTMS, and Loo et al
45
demonstrated that one session of LF-rTMS seemed
rather to deactivate the ACC than to activate it.
Altogether, the majority of successful rTMS treatment
studies correspond with pathophysiological models of
major depression that are based on dysfunctions within
fronto-cingulate networks,
23-25 although the direction of
the changes is not consistent over studies. 
Neuroendocrinology and rTMS
An important aspect of the physiology of rTMS could be
related to the endocrinological response of the HPA
axis.
46,47 Keck
48 proposed that rTMS influences occur at
the hypothalamic level, suggesting that the (dorsolateral)
prefrontal cortex participates in the rTMS-induced
blunted response of HPA activity. HF-rTMS would
inhibit cortisol-releasing hormone synthesis and release
(Figure 2). Some studies have examined this hypothesis
in depressed patients.
47 For instance, in a sample of
severely depressed patients, salivary cortisol concentra-
tions decreased immediately after one active left
DLPFC HF-rTMS session and not after sham rTMS.
48
Pridmore
50 observed normalization of the dexametha-
sone suppression test in a small sample of medicated
depressed subjects after multiple sessions of HF-rTMS.
In addition, in a sham-controlled left prefrontal HF-
rTMS trial, Szuba et al
51 found acute mood and serum
thyroid-stimulating hormone elevations in drug-free
depressed patients after each active stimulation session.
Mood improvement was only observed after active HF-
rTMS. These observations could imply that the clinical
effects of rTMS act in a similar way to pharmacological
interventions: clinical improvement after antidepressant
treatment has been associated with a normalization of
HPA system function and different antidepressants may
act in the same way in attenuating the HPA axis.
52,53
However, it has to be noted that in depressed patients
HPA system abnormalities are not consistently
observed.
47
Figure 2. Visualization of a theoretical working mechanism of HF-rTMS
applied to the DLPFC on the HPA-system in unipolar major
depression. In the left hand corner a figure-of-eight shaped
repetitive transcranial magnetic stimulation (rTMS) coil is
depicted. rTMS treatment results in increased neuronal activ-
ity in the (dorsolateral) prefrontal cortex, which through cor-
tico-subcortical trans-synaptic connections (presumably
through frontocingulate networks)
32 suppresses hypothalamic
and/or indirectly amygdala overactivity, resulting in CRH
decreases and ultimately in decreased salivary cortisol con-
centrations. In line with successful pharmacological interven-
tions, successful rTMS treatment results in normalization of
the negative feedback system.
46 The areas in red represent an
elevated neuronal activity. The blue areas represent the reverse,
a diminished level of neuronal activity. ACTH, adenocorti-
cotropic hormone DLPFC, dorsolateral prefrontal cortex; ACC,
anterior cingulate cortex; GR, glucocorticoid receptors; MR,
mineral-corticoid receptor; CRH, corticotrophin-releasing hor-
mone; ACTH: adenocorticotrope hormone; H, Hypothalamus;
P, Pituitary gland; A, Adrenal cortex; (-), inhibitory; (+) ,exci-
tatory 
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Neurotransmitter systems and rTMS
Only a few studies have examined the rTMS effects on
neurotransmitter systems in major depression. Because
rTMS treatment resulted in psychomotor symptom
improvement, such as a reduction in motor slowness in
bodily movement and speech, increased voice volume,
and facial inexpressivity, some authors suggested that
a possible working mechanism of action could be by
activating the dopaminergic system.
54,55 Indeed, several
brain imaging studies using dopaminergic ligands point
to an rTMS-related release in endogenous dopamine
when stimulating prefrontal cortical areas,
56,57 although
others found no impact on the dopaminergic system at
all.
58,59 In major depression, the serotonergic system has
been extensively investigated, and serotonin (5-HT) is
an important excitatory transmitter involved in HPA-
system regulation.
60 In a severely depressed medica-
tion-resistant sample, successful clinical outcome after
HF-rTMS treatment was associated with DLPFC 5-
HT2A receptor upregulation and hippocampal 5-HT2A
receptor downregulation, measured with 123I-5-I-
R91150 SPECT.
61 Interestingly, this prefrontal increase
of this type of postsynaptic receptor agrees with treat-
ment response findings after treatment with selective
serotonin uptake inhibitors (SSRIs) and electrocon-
vulsive therapy (ECT).
62,63 As clinical recovery is
reported to be associated with increased brain-derived
neurotrophic factor (BDNF) expression in the hip-
pocampus,
64 it was suggested that the observed 5-HT2A
receptor downregulation in the hippocampus would be
associated with BDNF increases in this area compara-
ble to the effects of most pharmacological antidepres-
sant agents.
65 However, as rTMS responders seem to be
resistant to acute mood changes after trypthophan
depletion,
66 it may be possible that the neurobiological
influence of rTMS does not only depend on the central
availability of serotonin to exert antidepressant effects.
In short, whether the rTMS effects are attributed to the
modulation of only the serotonergic system remains
unclear. A beneficial treatment outcome has been
related to glutaminergic increases under the stimulated
area (left DLPFC) in depressed patients.
44 From an
electrophysiological point of view, stimulation of the
DLPFC might influence 5-HT2A receptors in the hip-
pocampus via (glutaminergic) pyramidal neurons.
67
Furthermore, research on the chronic effects of TMS
on hippocampal evoked potentials demonstrates that
TMS is accompanied by changes in the local hip-
pocampal inhibitory circuits (γ-aminobutyric acid,
GABA).
68The implication of glutaminergic/GABAergic
deficits in major depression has been proposed, but to
date the influence of rTMS on the glutaminergic/
GABA system has only been demonstrated in healthy
individuals.
69,70 A single active HF-rTMS session
increased glutamate/glutamine levels in the prefrontal
cortices, suggesting that this application may act via the
stimulation of the glutaminergic prefrontal neurons.
69
Concerning the inhibitory effects, active rTMS resulted
in increases in cortical inhibition; however, in this study
only the left motor cortex was stimulated.
70
Neurotrophic factors and rTMS
Brain and endocrinological data indirectly suggest that
a clinical beneficial rTMS outcome affects neurotrophic
factors in the brain.
71 Animal studies already demon-
strated increases in the expression of BDNF in the rat
hippocampus after the application of long-term HF-
rTMS similar to antidepressant drug treatment and
ECT.
72 In a sample of drug-resistant depressed patients,
Zanardini et al
73 reported on a normalizing rTMS effect
of initially decreased serum BDNF. Yukimisa et al
74
demonstrated that changes in serum BDNF correlated
positively (rs=0.34) with changes on the 17-item
Hamilton Depression Rating Scale in all depressed
patients treated with HF-rTMS. These trend-like corre-
lations were found to be significant when comparing
responders with nonresponders; an increase of BDNF
levels was only observed in those patients who clinically
responded to the HF-rTMS treatment.
Conclusions
In unipolar depressed patients, beneficial rTMS treat-
ment has immediate and prolonged neurobiological
effects. Neurobiological data support the choice of the
left DLPFC as a valid rTMS target site to intervene
with the neuronal pathways deregulated in major
depression. The observed changes in a depression-
related neurocircuitry seem to agree with other suc-
cessful treatment modalities, such as pharmacological
antidepressant treatment and ECT. Although further
research is required, biological data indicate that
depressed patients with some kind of “preserved” cor-
tico-subcortical neurocircuitries could be susceptible to
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rTMS treatment. Displaying a metabolically more
active fronto-cingulate network at baseline indicates a
possible better clinical outcome. This observation is con-
sistent with the hypothesis that the synchronized mod-
ulation of “dysfunctional fronto-cingulate pathways” is
critical for illness remission.
23 In short, successful rTMS
treatment seems to result in a cascade of neurobiolog-
ical changes in brain areas linked with the stimulated
area, supporting the integrative model of action
depicted in Figures 1 and 2. Whether the rTMS effects
are modulated by NT systems or neurotrophic factors
remains to be clarified. ❏
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Mecanismos neurobiológicos de la 
estimulación magnética transcraneal 
repetitiva sobre los neurocircuitos 
subyacentes a la depresión unipolar
Desde hace casi dos décadas se dispone de la esti-
mulación magnética transcraneal (EMT) como una
herramienta clínica no invasora para tratar a los
pacientes con depresión mayor. En este período se
han examinado numerosos estudios clínicos y en
animales acerca de los parámetros de la EMT para
mejorar sus resultados clínicos. Sin embargo, los
mecanismos neurobiológicos a la base de los cam-
bios del ánimo siguen constituyendo un importante
foco de investigación. Además de tener un efecto
sobre los procesos neuroendocrinos, los sistemas de
neurotransmisión y los factores neurotróficos, la
EMT no solo puede afectar las regiones corticales
estimuladas, sino también las que están conectadas
con ellas. Por lo tanto, se revisarán los datos actua-
les en humanos acerca de los posibles mecanismos
neurobiológicos de la EMT repetitiva que participan
en los neurocircuitos disregulados de  la depresión
unipolar. Además, ya que la aplicación de la EMT
repetitiva se puede considerar como una interven-
ción neuronal “desde arriba hacia abajo”, la revi-
sión se centrará en las vías neuronales relacionadas
con el área estimulada y se presentará un modelo
de acción integrador.    
Mécanismes neurobiologiques de la 
stimulation magnétique transcrânienne
répétée (rTMS) sur le circuit neuronal 
sous-jacent dans la dépression unipolaire
Depuis presque 20 ans, la stimulation magnétique
transcrânienne (TMS) constitue un outil clinique
non invasif pour traiter les patients souffrant de
dépression majeure. Pendant ce temps, un grand
nombre d'études humaines et animales ont exa-
miné les paramètres de la TMS afin d’en améliorer
les résultats cliniques. Cependant, les mécanismes
neurobiologiques sous-tendant les modifications de
l’humeur restent un important sujet de recherche.
Outre l’effet sur les processus neuroendocriniens,
sur les systèmes de neurotransmission et les facteurs
neurotrophiques, la TMS toucherait non seulement
les régions corticales stimulées mais aussi celles qui
lui sont connectées. Nous allons donc analyser les
données humaines actuelles sur les mécanismes
neurobiologiques possibles de la rTMS impliqués
dans le dysfonctionnement des circuits neuronaux
dans la dépression unipolaire. De plus, la rTMS pou-
vant être considérée comme une technique neuro-
nale « descendante », nous nous consacrerons aux
voies neuronales liées aux aires stimulées et nous
présenterons un modèle d’action intégratif. 
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